Expression of human DNA topoisomerase II-α in squamous cell carcinoma of the larynx and its correlation with clinicopathologic variables

American Journal of Clinical Pathology

Volumn 130, Issue 6, 2008, Pages 934-939

  Shvero, Jacob ^a   Koren, Rumelia ^a,b   Shvili, Itzhak ^a   Yaniv, Eitan ^a   Sadov, Rima ^a   Hadar, Tuvia ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Larynx; Prognosis; Squamous cell carcinoma; Topoisomerase II index

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 58049196935     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPROG61USKCBEI     Document Type: Article

References (26)

1. Shaha AR, Shah JP. Carcinoma of the subglottic larynx. Am J Surg. 1982;144:456-458.
2. Ton-Van J, Lefebvre JL, Stern JC, et al. Comparison of surgery and radiotherapy in T1 and T2 glottic carcinomas. Am J Surg. 1991;162:337-340.
3. Morris MR, Canonico D, Blank C. A critical review of radiotherapy in the management of T1 glottic carcinoma. Am J Otolaryngol. 1994;15:276-280.
4. Koren R, Kugel V, Dekel Y, et al. Human DNA topoisomerase-II α expression as a prognostic factor for transitional cell carcinoma of the urinary bladder. BJU Int. 2003;91:489-492.
5. Heck MM, Earnshaw WC. Topoisomerase II: a specific marker for cell proliferation. J Cell Biol. 1986;103:2569-2581.
6. Capranuco G, Tinelli S, Austin CA, et al. Differential patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta. 1992;1132:43-48.
7. Juenke JM, Holden JA. The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues. Biochim Biophys Acta. 1993;1216:191-196.
8. Holden JA, Perkins SL, Snow GW, et al. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol. 1995;104:54-59.
9. Monnin KA, Bronstein IB, Gaffney D, et al. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-α and p-53 expression. Hum Pathol. 1999;30:384-391.
10. Lynch BJ, Guinee DG Jr, Holden JA. Human DNA topoisomerase II-α: a new marker of cell proliferation in invasive breast cancer. Hum Pathol. 1997;28:1180-1188.
11. Austin CA, Sng JH, Patel S, et al. Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta. 1993;1172:283-291.
12. Drake FH, Hofmann GA, Bartus HF, et al. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 1989;28:8154-8160.
13. Tsai-Pflugfelder M, Liu AA, Tewey KM, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A. 1988;85:7177-7181.
14. Jenkins JR, Ayton P, Jones T, et al. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localization of the gene to chromosome 3p24. Nucleic Acids Res. 1992;20:5587-5592.
15. Woessner RD, Mattern MR, Mirabelli CK, et al. Proliferation- and cell cyclic-dependent differences in the expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991;2:209-214.
16. Villman K, Stahl E, Liljegren G, et al. Topoisomerase II-α expression in different cell cycle phases in fresh human breast carcinomas. Mod Pathol. 2002;15:486-491.
17. Houlbrook S, Addison CM, Davies SL, et al. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer. 1995;72:1454-1461.
18. Tsai SC, Valkov N, Yang WM, et al. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet. 2000;26:349-353.
19. Cho KH, Pezzuto JM, Bolton JL, et al. Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity. Eur J Cancer. 2000;36:2146-2156.
20. Tortora G, Ciardiello F, Damiano V, et al. Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. Clin Cancer Res. 1995;1:49-56.
21. McClelland RA, Berger U, Miller LS, et al. Immunocytochemical assays for estrogen receptor in patients with breast cancer: relation to a biochemical assay and the outcome of therapy. J Clin Oncol. 1986;4:1171-1176.
22. Horibe Y, Murakami M, Komori K, et al. Expression of topoisomerase II α, Ki-67 and p53 in early stage laryngeal carcinomas not featuring vocal cord fixation. APMIS. 2000;108:689-696.
23. Deng G, Yang C, Chen W. The expression of Ki-67, topoII α in laryngeal squamous cell carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2005;19:396-398.
24. Fleming ID, Cooper JS, Henson DE, et al (American Joint Committee on Cancer), eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997.
25. Liu WW, Zeng ZY, Wu QL, et al. Overexpression of MMP-2 in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Otolaryngol Head Neck Surg. 2005;132:395-400.
26. Koren R, Rath-Wolfson L, Ram E, et al. Prognostic value of topoisomerase II in female breast cancer. Oncol Rep. 2004;12:915-919.